Market News AIOpen the app

HC Wainwright & Co. lowered its price target for Tango Therapeutics from $68.00 to $67.00 per share.

OpinionRead the original at moomoo.com
Neutral

HC Wainwright kept its Buy rating but lowered its target from $68 to $67 per share. These mixed views add no new evidence of a change in Tango's business outlook.

TNGX · Tango Therapeutics, Inc.

AI read · Neutral

The AI's read

The note gives two different signals: the firm kept its positive rating but lowered its estimate for the share price. It reports no new trial results or company changes, so it does not show a change in Tango's business outlook.

Get alerts for TNGX

Follow Tango Therapeutics, Inc. (TNGX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TNGX
Free on the App Store and Google Play, or on the web.